Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameHaixi Pharma
Stock Code02637
Company Full NameFujian Haixi Pharmaceuticals Co., Ltd.
IndustryBiotech & Pharma
Principal ActivitiesWe are a commercial-stage pharmaceutical company with integrated research and development, manufacturing and sales capabilities and a pipeline of innovative drugs in development. We have a diversified product portfolio and pipeline in the largest and fastest-growing therapeutic areas in China. As of the Latest Practicable Date, our commercialized product portfolio mainly comprises generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases; our innovative drug pipeline focuses on drugs in development for various indications, including an innovative oncology drug in development, a potential first oral drug for the treatment of wet age-related macular degeneration (wAMD)/diabetic macular edema (DME)/retinal vein occlusion (RVO) and two other innovative drugs in development at the preclinical stage for the treatment of oncology and respiratory system diseases.
Listing Date2025-10-20
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)Cangshan District Fuzhou, Fujian Province PRC Principal Place of 40/F, Dah Sing Financial Centre Business in Hong Kong 248 Queen’s Road East, Wanchai Hong Kong
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehxpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism B
Offer PriceHK$ 86.40 / shares
Offer Price RangeFinal offer price only, no range
Lot Size50 shares
Entry ThresholdHK$ 4,320
Par ValueRMB 1.0 / shares
Offer Period2025-10-09 to 2025-10-14
Global Offering Shares11,500,000 shares
HK Public Offer Shares (Initial)1,150,000 shares (10.0%)
Public Offer Lots (Initial)23,000lots (Pool A11,500lots,Pool B11,500lots)
International Placing Shares (Initial)10,350,000 shares (90.0%)
Offer Ratio~14.61%
Total Shares Post-IPO78,707,270 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share17.2%
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 993,600,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 50 HK$ 4,320
2 lots 100 HK$ 8,640
3 lots 150 HK$ 12,960
4 lots 200 HK$ 17,280
5 lots 250 HK$ 21,600
6 lots 300 HK$ 25,920
7 lots 350 HK$ 30,240
8 lots 400 HK$ 34,560
9 lots 450 HK$ 38,880
10 lots 500 HK$ 43,200
12 lots 600 HK$ 51,840
14 lots 700 HK$ 60,480
16 lots 800 HK$ 69,120
18 lots 900 HK$ 77,760
20 lots 1,000 HK$ 86,400
30 lots 1,500 HK$ 129,600
40 lots 2,000 HK$ 172,800
50 lots 2,500 HK$ 216,000
60 lots 3,000 HK$ 259,200
70 lots 3,500 HK$ 302,400
80 lots 4,000 HK$ 345,600
90 lots 4,500 HK$ 388,800
100 lots 5,000 HK$ 432,000
120 lots 6,000 HK$ 518,400
140 lots 7,000 HK$ 604,800
160 lots 8,000 HK$ 691,200
180 lots 9,000 HK$ 777,600
200 lots 10,000 HK$ 864,000
400 lots 20,000 HK$ 1,728,000
600 lots 30,000 HK$ 2,592,000
800 lots 40,000 HK$ 3,456,000
1,000 lots 50,000 HK$ 4,320,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,200 lots 60,000 HK$ 5,184,000
1,400 lots 70,000 HK$ 6,048,000
1,600 lots 80,000 HK$ 6,912,000
1,800 lots 90,000 HK$ 7,776,000
2,000 lots 100,000 HK$ 8,640,000
4,000 lots 200,000 HK$ 17,280,000
6,000 lots 300,000 HK$ 25,920,000
8,000 lots 400,000 HK$ 34,560,000
10,000 lots 500,000 HK$ 43,200,000
11,500 lots 575,000 HK$ 49,680,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 13.54B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 6,800,308,128
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioApproximately 39.0x (based on offer price HK$86.4 and 2024 EPS)
Profit/Loss StatusNet profit RMB 136.1 million
Period-End Cash BalanceRMB 38.3 million
Listing Expenses~HK$ 50,600,000
Listing Expenses / Funds Raised~5.09%
Total Pre-IPO InvestmentTo be extracted
First Day CloseLoading...
First Day OpenHK$ 102.00
First Day Change154.17%
Use of Proceeds
1、約52.0%或441.0百萬港元預期將用于持續投資于研發,以推進管線中的在研藥物并豐富產品組合; 2、約23.0%或195.0百萬港元預計將用于提升研發能力及尋求合作機會; 3、約8.0%或67.8百萬港元預計將用于增強商業化能力及擴大市場影響力; 4、約7.0%或59.4百萬港元預計將用于改善和優化研發和生產系統; 5、約10.0%或84.8百萬港元預計將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940
Sponsor cum Overall Coordinator (2)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940
Overall Coordinators (3)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
Joint Global Coordinators (3)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
Joint Bookrunners (8)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 民银证券有限公司 CE APU820 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (8)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 民银证券有限公司 CE APU820 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Capital Market Intermediaries (8)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 民银证券有限公司 CE APU820 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855

Service Providers

RoleInstitution
Legal Advisor to Company 海问律师事务所有限法律责任合伙
亚司特律师事务所
北京德恒律师事务所
竞天公诚律师事务所
Legal Advisor to Sponsors/Underwriters 周俊轩律师事务所与北京市通商律师事务所联营
嘉源律师事务所
Auditor and Reporting Accountant 德勤‧关黄陈方会计师行
Industry Advisor 灼识行业咨询有限公司
Compliance Advisor ORIENT CAPITAL (HONG KONG) LIMITED CE BDN128
Receiving Banks 招商永隆银行有限公司
中信银行(国际)有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest Oriental 22,000,000 USD 1,981,700 17.23% 2.52% 6 months 2026-04-20

Directors & Management

PositionChinese nameEnglish Name
Chairman / Executive Director康心汕Kang Xinshan
Company SecretaryMs. Zhang JunhuanMs. Zhang Junhuan
Non-Executive Director许冬Xu Dong
Independent Non-Executive Director龚为民Gong Weimin
Executive DirectorFeng Yan
Non-Executive Director王忻琨Wang Xinkun
Independent Non-Executive Director王珊珊Wang Shan Shan FlatA
Executive DirectorChen Guangming
Independent Non-Executive Director蒲美婷Pu Meiting
Executive Director陈枢仪Chen Shuyi
Independent Non-Executive Director陈霞Chen Xia
Independent Non-Executive Director吴江Wu Jiang
Independent Non-Executive Director许丽霞Xu Lixia

Major Shareholders

Major Shareholders & HoldingsThe Controlling Shareholders, Dr. Kang Xinshan, Ms. Feng Yan and Tairuihe Investment, together hold approximately 41.17% of the total issued share capital of the Company. Immediately after the completion of the Global Offering, the Controlling Shareholders will own and control approximately 35.15% of the total issued share capital of the Company.
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO saw an extreme oversubscription ratio of 3165.1x, indicating intense investor enthusiasm. Overall hit rate was a mere 6.82%, meaning only a small fraction of applicants received allocations. The offer price was fixed at HKD 86.4 with no disclosed range, and the reallocation was triggered, suggesting strong institutional demand as well. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

The A-tail (50,000 lots) expected allocation was 0.3272 lots, only marginally below the B-head (60,000 lots) at 0.3482 lots. This near-parity indicates severe inefficiency, as the additional 10,000 lots yield a negligible increment. Given the higher capital and broker fees for B-head, the A-tail tier appears more cost-effective, though actual broker fee structures vary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Mainland investors accounted for 63.5% of successful applicants, signaling robust cross-border demand for this biopharmaceutical IPO. The gender split was 63% male and 37% female, and the average age was 43.2, reflecting a slightly older and male-skewed investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Haixi Pharma (02637) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect